Scarlett steps down as CEO of Geron
Plus: Purespring names Haseeb Ahmad CEO, and updates from Cellevate and Moffitt Cancer Center
John Scarlett is leaving Geron Corp. (NASDAQ:GERN) as chairman, president and CEO, effective March 31, after more than a decade at the company. He has been Geron’s CEO since his arrival in 2011; he added the title of president in 2012, and became chairman in 2018. Dawn Carter Bir, a Geron director, will be interim president and CEO while the company searches for a replacement. Under Scarlett’s leadership, Geron obtained FDA approval of Rytelo imetelstat to treat myelodysplastic syndromes after 34 years in business; the company said Tuesday that the drug is now also approved by EMA.
Kidney disease company Purespring Therapeutics Ltd. named Haseeb Ahmad as CEO and board member. Ahmad, who succeeds Julian Hanak, was most recently president of Europe at Novartis AG (SIX:NOVN; NYSE:NVS). ...